Superselective Citicoline and Verapamil for Ischemic Neuroprotection and Greater Effective Response
Status:
Withdrawn
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
This is a phase 1, blinded-outcome, randomized, placebo controlled study to investigate the
safety and feasibility of super-selective intra-arterial administration of verapamil and
citicoline immediately following successful endovascular thrombectomy as a potential
neuroprotective synergistic therapeutic strategy in emergent large vessel occlusion stroke.
This trial represents the first time that citicoline will be evaluated in human subjects as a
superselectively administered neuroprotective agent administered in an acute time frame as an
adjunct to intra-arterial thrombectomy. Furthermore, it will represent the first trial to
evaluate combinational therapy for acute stroke neuroprotection.